The two healthcare software companies believe that this joint venture will solidify their presence in the US oncology market.
They claim that combining IntrinsiQ’s IntelliDose chemotherapy management solution and Pulse’s Patient Relationship Management solution will provide oncology practices with unprecedented efficiency in patient flow, workflow and cash flow, and deliver patient safety through automation and standards built specifically for each individual practice.
In addition, with the combined software, oncology practices will not have to perform double entries or work in two different systems.
IntelliDose is expected to seamlessly integrate into the Pulse Patient Relationship Management solution to provide oncologists with a comprehensive software option. The integrated offering will allow clinicians to easily interact with patient demographics, appointment information, lab results, medications, diagnoses, nurses’ and doctors’ notes, and more.
The relationship with IntrinsiQ is a strategic move that completes the workflow cycle for oncology practices using the Pulse Patient Relationship Management solution, said Basil Hourani, president of Pulse. The integration of Chemotherapy Management into Pulse oncology-specific electronic health records and revenue cycle management provides oncology clients with unparalleled workflow that promotes patient safety and peace of mind and solidifies the software as the premier oncology software product offering.
